References

1. Sasmita, A.O.; Wong, Y.P.; Ling, A.P.K. Biomarkers and therapeutic advances in glioblastoma multiforme. Asia. Pac. J. Clin. Oncol. 2018, 14, 40–51.
2. McLendon, R.; Friedman, A.; Bigner, D.; Van Meir, E.G.; Brat, D.J.; Mastrogianakis, G.M.; Olson, J.J.; Mikkelsen, T.; Lehman, N.; Aldape, K.; et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061–1068.
3. Brennan, C.W.; Verhaak, R.G.W.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155, 462.
4. Huang, P.H.; Xu, A.M.; White, F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2009, 2.
5. Ohgaki, H.; Kleihues, P. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 2013, 19, 764–772.
6. Arcella, A.; Limanaqi, F.; Ferese, R.; Biagioni, F.; Oliva, M.A.; Storto, M.; Fanelli, M.; Gambardella, S.; Fornai, F. Dissecting molecular features of gliomas: Genetic loci and validated biomarkers. Int. J. Mol. Sci. 2020, 21, 685.
7. De Vleeschouwer, S. (Ed.) Glioblastoma; Codon Publications: Brisbane, Australia, 2017; ISBN 9780994438126.
8. Laezza, C.; D’Alessandro, A.; Di Croce, L.; Picardi, P.; Ciaglia, E.; Pisanti, S.; Malfitano, A.M.; Comegna, M.; Faraonio, R.; Gazzerro, P.; et al. P53 regulates the mevalonate pathway in human glioblastoma multiforme. Cell Death Dis. 2015, 6, e1909.
9. Verreault, M.; Schmitt, C.; Goldwirt, L.; Pelton, K.; Haidar, S.; Levasseur, C.; Guehennec, J.; Knoff, D.; Labussière, M.; Marie, Y.; et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin. Cancer Res. 2016, 22, 1185–1196.
10. Stokoe, D. PTEN. Curr. Biol. 2001, 11, R502.
11. El-Khayat, S.M.; Arafat, W.O. Therapeutic strategies of recurrent glioblastoma and its molecular pathways “Lock up the beast”. Ecancermedicalscience 2021, 15, 1176.
12. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P.L.; Burkhard, C.; Schüler, D.; Probst-Hensch, N.M.; Maiorka, P.C.; et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res. 2004, 64, 6892–6899.
13. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 Mutations in Gliomas. N. Engl. J. Med. 2009, 360, 765–773.
14. Picca, A.; Berzero, G.; Di Stefano, A.L.; Sanson, M. The clinical use of IDH1 and IDH2 mutations in gliomas. Expert Rev. Mol. Diagn. 2018, 18, 1041–1051.
15. Mondesir, J.; Willekens, C.; Touat, M.; de Botton, S. IDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives. J. Blood Med. 2016, 7, 171–180.
16. Jiao, Y.; Killela, P.J.; Reitman, Z.J.; Rasheed, B.A.; Heaphy, C.M.; de Wilde, R.F.; Rodriguez, F.J.; Rosemberg, S.; Oba-Shinjo, S.M.; Marie, S.K.N.; et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012, 3, 709–722.
17. Nikiforova, M.N.; Hamilton, R.L. Molecular diagnostics of gliomas. Arch. Pathol. Lab. Med. 2011, 135, 558–568.
18. Yang, P.; Zhang, W.; Wang, Y.; Peng, X.; Chen, B.; Qiu, X.; Li, G.; Li, S.; Wu, C.; Yao, K.; et al. IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry. Oncotarget 2015, 6, 40896–40906.
19. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol. 2016, 131, 803–820.
20. Oronsky, B.; Reid, T.R.; Oronsky, A.; Sandhu, N.; Knox, S.J. A Review of Newly Diagnosed Glioblastoma. Front. Oncol. 2021, 10.
21. Safa, A.R.; Saadatzadeh, M.R.; Cohen-Gadol, A.A.; Pollok, K.E.; Bijangi-Vishehsaraei, K. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis. 2015, 2, 152–163.
22. Garnett, J.; Chumbalkar, V.; Vaillant, B.; Gururaj, A.E.; Hill, K.S.; Latha, K.; Yao, J.; Priebe, W.; Colman, H.; Elferink, L.A.; et al. Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 2013, 15, 73–84.
23. Silantyev, A.S.; Falzone, L.; Libra, M.; Gurina, O.I.; Kardashova, K.S.; Nikolouzakis, T.K.; Nosyrev, A.E.; Sutton, C.W.; Mitsias, P.D.; Tsatsakis, A. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells 2019, 8, 863.
24. Montemurro, N. Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. J. Neurol. Surg. A 2020, 81, 64–70.
25. Eoli, M.; Menghi, F.; Bruzzone, M.G.; De Simone, T.; Valletta, L.; Pollo, B.; Bissola, L.; Silvani, A.; Bianchessi, D.; D’Incerti, L.; et al. Methylation of O6-methylguanine DNA methytransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin. Cancer Res. 2007, 13, 2606–2613.
26. Szopa, W.; Burley, T.A.; Kramer-Marek, G.; Kaspera, W. Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives. Biomed. Res. Int. 2017, 2017.
27. Verhaak, R.G.W.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110.
28. Llaguno, S.R.A.; Parada, L.F. Cell of origin of glioma: Biological and clinical implications. Br. J. Cancer 2016, 115, 1445–1450.
29. Gómez-Oliva, R.; Domínguez-García, S.; Carrascal, L.; Abalos-Martínez, J.; Pardillo-Díaz, R.; Verástegui, C.; Castro, C.; Nunez-Abades, P.; Geribaldi-Doldán, N. Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. Front. Oncol. 2021, 10.
30. Jovčevska, I. Genetic secrets of long-term glioblastoma survivors. Bosn. J. Basic Med. Sci. 2019, 19, 116–124.
31. Ceccarelli, M.; Barthel, F.P.; Malta, T.M.; Sabedot, T.S.; Salama, S.R.; Murray, B.A.; Morozova, O.; Newton, Y.; Radenbaugh, A.; Pagnotta, S.M.; et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 2016, 164, 550–563.
32. Steed, T.C.; Treiber, J.M.; Patel, K.; Ramakrishnan, V.; Merk, A.; Smith, A.R.; Carter, B.S.; Dale, A.M.; Chow, L.M.L.; Chen, C.C. Differential localization of glioblastoma subtype: Implications on glioblastoma pathogenesis. Oncotarget 2016, 7, 24899–24907.
33. Sidaway, P. CNS cancer: Glioblastoma subtypes revisited. Nat. Rev. Clin. Oncol. 2017, 14, 587.
34. Dunlap, J.C.; Loros, J.J.; DeCoursey, P.J. (Eds.) Chronobiology: Biological Timekeeping; Sinauer Associates: Sunderland, MA, USA, 2004; ISBN 087893149X.
35. Takahashi, J.S.; Hong, H.K.; Ko, C.H.; McDearmon, E.L. The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat. Rev. Genet. 2008, 9, 764–775.
36. Golombek, D.A.; Rosenstein, R.E. Physiology of circadian entrainment. Physiol. Rev. 2010, 90, 1063–1102.
37. Welsh, D.K.; Takahashi, J.S.; Kay, S.A. Suprachiasmatic nucleus: Cell autonomy and network properties. Annu. Rev. Physiol. 2009, 72, 551–577.
38. Guido, M.E.; Goguen, D.; De Guido, L.; Robertson, H.A.; Rusak, B. Circadian and photic regulation of immediate-early gene expression in the hamster suprachiasmatic nucleus. Neuroscience 1999, 90, 555–571.
39. Guido, M.E.; Garbarino-Pico, E.; Contin, M.A.; Valdez, D.J.; Nieto, P.S.; Verra, D.M.; Acosta-Rodriguez, V.A.; de Zavalía, N.; Rosenstein, R.E. Inner retinal circadian clocks and non-visual photoreceptors: Novel players in the circadian system. Prog. Neurobiol. 2010, 92, 484–504.
40. Yamazaki, S.; Numano, R.; Abe, M.; Hida, A.; Takahashi, R.I.; Ueda, M.; Block, G.D.; Sakaki, Y.; Menaker, M.; Tei, H. Resetting central and peripheral circadian oscillators in transgenic rats. Science 2000, 288, 682–685.
41. Huang, X.-L.; Fu, C.-J.; Bu, R.-F. Role of Circadian Clocks in the Development and Therapeutics of Cancer. J. Int. Med. Res. 2011, 39.
42. Kubo, T.; Ozasa, K.; Mikami, K.; Wakai, K.; Fujino, Y.; Watanabe, Y.; Miki, T.; Nakao, M.; Hayashi, K.; Suzuki, K.; et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: Findings from the Japan Collaborative Cohort Study. Am. J. Epidemiol. 2006, 164, 549–555.
43. Masri, S.; Sassone-Corsi, P. The emerging link between cancer, metabolism, and circadian rhythms. Nat. Med. 2018, 24, 1795–1803.
44. Green, C.B.; Takahashi, J.S.; Bass, J. The Meter of Metabolism. Cell 2008, 134, 728–742.
45. Hardin, P.E.; Hall, J.C.; Rosbash, M. Feedback of the Drosophila period gene product on circadian cycling of its messenger RNA levels. Nature 1990, 343, 536–540.
46. Buhr, E.D.; Takahashi, J.S. Molecular components of the mammalian circadian clock. Handb. Exp. Pharmacol. 2013, 217, 3–27.
47. Lee, C.; Etchegaray, J.P.; Cagampang, F.R.A.; Loudon, A.S.I.; Reppert, S.M. Posttranslational mechanisms regulate the mammalian circadian clock. Cell 2001, 107, 855–867.
48. Eide, E.J.; Kang, H.; Crapo, S.; Gallego, M.; Virshup, D.M. Casein kinase I in the mammalian circadian clock. Methods Enzymol. 2005, 393, 408–418.
49. Godinho, S.I.H.; Maywood, E.S.; Shaw, L.; Tucci, V.; Barnard, A.R.; Busino, L.; Pagano, M.; Kendall, R.; Quwailid, M.M.; Romero, M.R.; et al. The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science 2007, 316, 897–900.
50. Shirogane, T.; Jin, J.; Ang, X.L.; Harper, J.W. SCFβ-TRCP controls Clock-dependent transcription via casein kinase 1-dependent degradation of the mammalian period-1 (Per1) protein. J. Biol. Chem. 2005, 280, 26863–26872.
51. Siepka, S.M.; Yoo, S.H.; Park, J.; Song, W.; Kumar, V.; Hu, Y.; Lee, C.; Takahashi, J.S. Circadian Mutant Overtime Reveals F-box Protein FBXL3 Regulation of Cryptochrome and Period Gene Expression. Cell 2007, 129, 1011–1023.
52. Yoo, S.H.; Mohawk, J.A.; Siepka, S.M.; Shan, Y.; Huh, S.K.; Hong, H.K.; Kornblum, I.; Kumar, V.; Koike, N.; Xu, M.; et al. Competing E3 ubiquitin ligases govern circadian periodicity by degradation of CRY in nucleus and cytoplasm. Cell 2013, 152, 1091–1105.
53. Preitner, N.; Damiola, F.; Zakany, J.; Duboule, D.; Albrecht, U.; Schibler, U. The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell 2002, 110, 251–260.
54. Sato, T.K.; Panda, S.; Miraglia, L.J.; Reyes, T.M.; Rudic, R.D.; McNamara, P.; Naik, K.A.; Fitzgerald, G.A.; Kay, S.A.; Hogenesch, J.B. A functional genomics strategy reveals rora as a component of the mammalian circadian clock. Neuron 2004, 43, 527–537.
55. Sancar, G.; Brunner, M. Circadian clocks and energy metabolism. Cell. Mol. Life Sci. 2014, 71, 2667–2680.
56. Fu, L.; Kettner, N.M. The circadian clock in cancer development and therapy. In Progress in Molecular Biology and Translational Science; Elsevier: Amsterdam, The Netherlands, 2013; Volume 119, pp. 221–282. ISBN 9780123969712.
57. Panda, S.; Antoch, M.P.; Miller, B.H.; Su, A.I.; Schook, A.B.; Straume, M.; Schultz, P.G.; Kay, S.A.; Takahashi, J.S.; Hogenesch, J.B. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002, 109, 307–320.
58. Miller, B.H.; McDearmon, E.L.; Panda, S.; Hayes, K.R.; Zhang, J.; Andrews, J.L.; Antoch, M.P.; Walker, J.R.; Esser, K.A.; Hogenesch, J.B.; et al. Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc. Natl. Acad. Sci. USA 2007, 104, 3342–3347.
59. Arafa, K.; Emara, M. Insights About Circadian Clock and Molecular Pathogenesis in Gliomas. Front. Oncol. 2020, 10, 199.
60. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
61. Sulli, G.; Lam, M.T.Y.; Panda, S. Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment. Trends Cancer 2019, 5, 475–494.
62. Shafi, A.A.; Knudsen, K.E. Cancer and the circadian clock. Cancer Res. 2019, 79, 3806–3814.
63. Soták, M.; Sumová, A.; Pácha, J. Cross-talk between the circadian clock and the cell cycle in cancer. Ann. Med. 2014, 46, 221–232.
64. Shostak, A. Circadian clock, cell division, and cancer: From molecules to organism. Int. J. Mol. Sci. 2017, 18, 873.
65. Farshadi, E.; Yan, J.; Leclere, P.; Goldbeter, A.; Chaves, I.; van der Horst, G.T.J. The positive circadian regulators CLOCK and BMAL1 control G2/M cell cycle transition through Cyclin B1. Cell Cycle 2019, 18, 16–33.
66. Kiessling, S.; Beaulieu-Laroche, L.; Blum, I.D.; Landgraf, D.; Welsh, D.K.; Storch, K.F.; Labrecque, N.; Cermakian, N. Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol. 2017, 15, 13.
67. Hoffman, A.E.; Zheng, T.; Ba, Y.; Stevens, R.G.; Yi, C.H.; Leaderer, D.; Zhu, Y. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways. BMC Cancer 2010, 10, 110.
68. Lee, S.; Donehower, L.A.; Herron, A.J.; Moore, D.D.; Fu, L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS ONE 2010, 5, e10995.
69. Fu, L.; Pelicano, H.; Liu, J.; Huang, P.; Lee, C.C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002, 111, 41–50.
70. Gotoh, T.; Vila-Caballer, M.; Santos, C.S.; Liu, J.; Yang, J.; Finkielstein, C.V. The circadian factor Period 2 modulates p53 stability and transcriptional activity in unstressed cells. Mol. Biol. Cell 2014, 25, 3081–3093.
71. Gotoh, T.; Kim, J.K.; Liu, J.; Vila-Caballer, M.; Stauffer, P.E.; Tyson, J.J.; Finkielstein, C.V. Model-driven experimental approach reveals the complex regulatory distribution of p53 by the circadian factor period 2. Proc. Natl. Acad. Sci. USA 2016, 113, 13516–13521.
72. Gotoh, T.; Vila-Caballer, M.; Liu, J.; Schiffhauer, S.; Finkielstein, C.V. Association of the circadian factor Period 2 to p53 influences p53’s function in DNA-damage signaling. Mol. Biol. Cell 2015, 26, 359–372.
73. Zhanfeng, N.; Chengquan, W.; Hechun, X.; Jun, W.; Lijian, Z.; Dede, M.; Wenbin, L.; Lei, Y. Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway. Oncotarget 2016, 7, 27350–27362.
74. Relógio, A.; Thomas, P.; Medina-Pérez, P.; Reischl, S.; Bervoets, S.; Gloc, E.; Riemer, P.; Mang-Fatehi, S.; Maier, B.; Schäfer, R.; et al. Ras-Mediated Deregulation of the Circadian Clock in Cancer. PLoS Genet. 2014, 10, e1004338.
75. El-Athman, R.; Genov, N.N.; Mazuch, J.; Zhang, K.; Yu, Y.; Fuhr, L.; Abreu, M.; Li, Y.; Wallach, T.; Kramer, A.; et al. The Ink4a/Arf locus operates as a regulator of the circadian clock modulating RAS activity. PLoS Biol. 2017, 15, e2002940.
76. Wagner, P.M.; Sosa Alderete, L.G.; Gorné, L.D.; Gaveglio, V.; Salvador, G.; Pasquaré, S.; Guido, M.E. Proliferative Glioblastoma Cancer Cells Exhibit Persisting Temporal Control of Metabolism and Display Differential Temporal Drug Susceptibility in Chemotherapy. Mol. Neurobiol. 2019, 56, 1276–1292.
77. Marquez, S.; Crespo, P.; Carlini, V.; Garbarino-Pico, E.; Baler, R.; Caputto, B.L.; Guido, M.E. The metabolism of phospholipids oscillates rhythmically in cultures of fibroblasts and is regulated by the clock protein PERIOD 1. FASEB J. 2004, 18, 519–521.
78. Verlande, A.; Masri, S. Circadian Clocks and Cancer: Timekeeping Governs Cellular Metabolism. Trends Endocrinol. Metab. 2019, 30, 445–458.
79. Méndez, I.; Díaz-Muñoz, M. Circadian and metabolic perspectives in the role played by NADPH in cancer. Front. Endocrinol. 2018, 9, 15.
80. Dyar, K.A.; Lutter, D.; Artati, A.; Ceglia, N.J.; Liu, Y.; Armenta, D.; Jastroch, M.; Schneider, S.; de Mateo, S.; Cervantes, M.; et al. Atlas of Circadian Metabolism Reveals System-wide Coordination and Communication between Clocks. Cell 2018, 174, 1571.e11–1585.e11.
81. Vollmers, C.; Gill, S.; DiTacchio, L.; Pulivarthy, S.R.; Le, H.D.; Panda, S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc. Natl. Acad. Sci. USA 2009, 106, 21453–21458.
82. Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47.
83. Scheiermann, C.; Gibbs, J.; Ince, L.; Loudon, A. Clocking in to immunity. Nat. Rev. Immunol. 2018, 18, 423–437.
84. Hadadi, E.; Acloque, H. Role of circadian rhythm disorders on EMT and tumour-immune interactions in endocrine-related cancers. Endocr. Relat. Cancer 2021, 28, R67–R80.
85. Matsunaga, N.; Kohno, Y.; Kakimoto, K.; Hayashi, A.; Koyanagi, S.; Ohdo, S. Influence of CLOCK on cytotoxicity induced by diethylnitrosamine in mouse primary hepatocytes. Toxicology 2011, 280, 144–151.
86. Wu, Y.; Sato, F.; Bhawal, U.K.; Kawamoto, T.; Fujimoto, K.; Noshiro, M.; Seino, H.; Morohashi, S.; Kato, Y.; Kijima, H. BHLH transcription factor DEC2 regulates pro-apoptotic factor bim in human oral cancer HSC-3 cells. Biomed. Res. 2012, 33, 75–82.
87. Wang, J.; Mauvoisin, D.; Martin, E.; Atger, F.; Galindo, A.N.; Dayon, L.; Sizzano, F.; Palini, A.; Kussmann, M.; Waridel, P.; et al. Nuclear Proteomics Uncovers Diurnal Regulatory Landscapes in Mouse Liver. Cell Metab. 2017, 25, 102–117.
88. Gery, S.; Komatsu, N.; Baldjyan, L.; Yu, A.; Koo, D.; Koeffler, H.P. The Circadian Gene Per1 Plays an Important Role in Cell Growth and DNA Damage Control in Human Cancer Cells. Mol. Cell 2006, 22, 375–382.
89. Kang, T.H.; Leem, S.H. Modulation of ATR-mediated DNA damage checkpoint response by cryptochrome 1. Nucleic Acids Res. 2014, 42, 4427–4434.
90. Kang, T.H.; Reardon, J.T.; Kemp, M.; Sancar, A. Orcadian oscillation of nucleotide excision repair in mammalian brain. Proc. Natl. Acad. Sci. USA 2009, 106, 2864–2867.
91. Papp, S.J.; Huber, A.L.; Jordan, S.D.; Kriebs, A.; Nguyen, M.; Moresco, J.J.; Yates, J.R.; Lamia, K.A. DNA damage shifts circadian clock time via Hausp-dependent Cry1 stabilization. eLife 2015, 4, e04883.
92. Oklejewicz, M.; Destici, E.; Tamanini, F.; Hut, R.A.; Janssens, R.; van der Horst, G.T.J. Phase Resetting of the Mammalian Circadian Clock by DNA Damage. Curr. Biol. 2008, 18, 286–291.
93. Kolinjivadi, A.M.; Chong, S.T.; Ngeow, J. Molecular connections between circadian rhythm and genome maintenance pathways. Endocr. Relat. Cancer 2021, 28, R55–R66.
94. Dong, Z.; Zhang, G.; Qu, M.; Gimple, R.C.; Wu, Q.; Qiu, Z.; Prager, B.C.; Wang, X.; Kim, L.J.Y.; Morton, A.R.; et al. Targeting glioblastoma stem cells through disruption of the circadian clock. Cancer Discov. 2019, 9, 1556–1573.
95. Li, A.; Lin, X.; Tan, X.; Yin, B.; Han, W.; Zhao, J.; Yuan, J.; Qiang, B.; Peng, X. Circadian gene clock contributes to cell proliferation and migration of glioma and is directly regulated by tumor-suppressive miR-124. FEBS Lett. 2013, 587, 2455–2460.
96. Chang, W.H.; Lai, A.G. Timing gone awry: Distinct tumour suppressive and oncogenic roles of the circadian clock and crosstalk with hypoxia signalling in diverse malignancies. J. Transl. Med. 2019, 17, 132.
97. Chen, P.; Hsu, W.H.; Chang, A.; Tan, Z.; Lan, Z.; Zhou, A.; Spring, D.J.; Lang, F.F.; Wang, Y.A.; Depinho, R.A. Circadian regulator CLOCK recruits immune-suppressive microglia into the GBM tumor microenvironment. Cancer Discov. 2020, 10, 371–381.
98. Crespo, I.; Tão, H.; Nieto, A.B.; Rebelo, O.; Domingues, P.; Vital, A.L.; Patino, M.D.C.; Barbosa, M.; Lopes, M.C.; Oliveira, C.R.; et al. Amplified and Homozygously Deleted Genes in Glioblastoma: Impact on Gene Expression Levels. PLoS ONE 2012, 7, e46088.
99. Chen, Z.; Liu, P.; Li, C.; Luo, Y.; Chen, I.; Liang, W.; Chen, X.; Feng, Y.; Xia, H.; Wang, F. Deregulated expression of the clock genes in gliomas. Technol. Cancer Res. Treat. 2013, 12, 91–97.
100. Madden, M.H.; Anic, G.M.; Thompson, R.C.; Nabors, L.B.; Olson, J.J.; Browning, J.E.; Monteiro, A.N.; Egan, K.M. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control 2014, 25, 25–32.
101. Wang, F.; Li, C.; Chen, L. The Circadian Gene Clock Plays an Important Role in Cell Apoptosis and the DNA Damage Response In Vitro. Technol. Cancer Res. Treat. 2016, 15, 480–486.
102. Wang, Z.; Su, G.; Dai, Z.; Meng, M.; Zhang, H.; Fan, F.; Liu, Z.; Zhang, L.; Weygant, N.; He, F.; et al. Circadian clock genes promote glioma progression by affecting tumour immune infiltration and tumour cell proliferation. Cell Prolif. 2021, 54, e12988.
103. Wagner, P.M.; Prucca, C.G.; Velazquez, F.N.; Sosa Alderete, L.G.; Caputto, B.L.; Guido, M.E. Temporal regulation of tumor growth in nocturnal mammals: In vivo studies and chemotherapeutical potential. FASEB J. 2021, 35, e21231.
104. Slat, E.A.; Sponagel, J.; Marpegan, L.; Simon, T.; Kfoury, N.; Kim, A.; Binz, A.; Herzog, E.D.; Rubin, J.B. Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. J. Biol. Rhythm. 2017, 32, 121–129.
105. Jung, C.H.; Kim, E.M.; Park, J.K.; Hwang, S.G.; Moon, S.K.; Kim, W.J.; Um, H.D. Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway. Oncol. Rep. 2013, 29, 2109–2113.
106. Gwon, D.H.; Lee, W.Y.; Shin, N.; Kim, S.I.; Jeong, K.; Lee, W.H.; Kim, D.W.; Hong, J.; Lee, S.Y. BMAL1 suppresses proliferation, migration, and invasion of U87MG cells by downregulating cyclin b1, phospho-AKT, and metalloproteinase-9. Int. J. Mol. Sci. 2020, 21, 2352.
107. Khan, S.; Liu, Y.; Siddique, R.; Nabi, G.; Xue, M.; Hou, H. Impact of chronically alternating light-dark cycles on circadian clock mediated expression of cancer (Glioma)-related genes in the brain. Int. J. Biol. Sci. 2019, 15, 1816–1834.
108. Xia, H.C.; Niu, Z.F.; Ma, H.; Cao, S.Z.; Hao, S.C.; Liu, Z.T.; Wang, F. Deregulated expression of the Per1 and Per2 in human gliomas. Can. J. Neurol. Sci. 2010, 37, 365–370.
109. Zhu, L.; Wang, Q.; Hu, Y.; Wang, F. The circadian gene PER1 plays an important role in radiation-induced apoptosis and DNA damage in glioma. Asian Pac. J. Cancer Prev. 2019, 20, 2195–2201.
110. Zhanfeng, N.; Yanhui, L.; Zhou, F.; Shaocai, H.; Guangxing, L.; Hechun, X. Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo. Oncotarget 2015, 6, 9951–9958.
111. Gao, Y.; Wu, Y.; Zhang, N.; Yuan, H.; Wang, F.; Xu, H.; Yu, J.; Ma, J.; Hou, S.; Cao, X. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87-MG cells. Mol. Med. Rep. 2021, 23.
112. Wang, F.; Luo, Y.; Li, C.; Chen, L. Correlation between deregulated expression of PER2 gene and degree of glioma malignancy. Tumori 2014, 100, e266–e272.
113. Ma, D.; Hou, L.; Xia, H.; Li, H.; Fan, H.; Jia, X.; Niu, Z. PER2 inhibits proliferation and stemness of glioma stem cells via the Wnt/ß-catenin signaling pathway. Oncol. Rep. 2020, 44, 533–542.
114. Luo, Y.; Wang, F.; Chen, L.A.; Chen, X.W.; Chen, Z.J.; Liu, P.F.; Li, F.F.; Li, C.Y.; Liang, W. Deregulated expression of Cry1 and Cry2 in human gliomas. Asian Pac. J. Cancer Prev. 2012, 13, 5725–5728.
115. Fan, W.; Caiyan, L.; Ling, Z.; Jiayun, Z. Aberrant rhythmic expression of cryptochrome2 regulates the radiosensitivity of rat gliomas. Oncotarget 2017, 8, 77809–77818.
116. Yu, M.; Li, W.; Wang, Q.; Wang, Y.; Lu, F. Circadian regulator NR1D2 regulates glioblastoma cell proliferation and motility. Oncogene 2018, 37, 4838–4853.
117. Wagner, P.M.; Monjes, N.M.; Guido, M.E. Chemotherapeutic Effect of SR9009, a REV-ERB Agonist, on the Human Glioblastoma T98G Cells. ASN Neuro 2019, 11.
118. Sulli, G.; Rommel, A.; Wang, X.; Kolar, M.J.; Puca, F.; Saghatelian, A.; Plikus, M.V.; Verma, I.M.; Panda, S. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature 2018, 553, 351–355.
119. Wang, F.; Chen, Q.X. The analysis of deregulated expression of the timeless genes in gliomas. J. Cancer Res. Ther. 2018, 14, S708–S712.
120. Razorenova, O.V. Brain and muscle ARNT-like protein BMAL1 regulates ROS homeostasis and senescence: A possible link to hypoxia-inducible factor-mediated pathway. Cell Cycle 2012, 11, 213.
121. Hatanaka, F.; Matsubara, C.; Myung, J.; Yoritaka, T.; Kamimura, N.; Tsutsumi, S.; Kanai, A.; Suzuki, Y.; Sassone-Corsi, P.; Aburatani, H.; et al. Genome-Wide Profiling of the Core Clock Protein BMAL1 Targets Reveals a Strict Relationship with Metabolism. Mol. Cell. Biol. 2010, 30, 5636–5648.
122. Khapre, R.V.; Kondratova, A.A.; Susova, O.; Kondratov, R.V. Circadian clock protein BMAL1 regulates cellular senescence in vivo. Cell Cycle 2011, 10, 4162–4169.
123. Cho, H.; Zhao, X.; Hatori, M.; Yu, R.T.; Barish, G.D.; Lam, M.T.; Chong, L.W.; Ditacchio, L.; Atkins, A.R.; Glass, C.K.; et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 2012, 485, 123–127.
124. Solt, L.A.; Wang, Y.; Banerjee, S.; Hughes, T.; Kojetin, D.J.; Lundasen, T.; Shin, Y.; Liu, J.; Cameron, M.D.; Noel, R.; et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature 2012, 485, 62–68.
125. Woldt, E.; Sebti, Y.; Solt, L.A.; Duhem, C.; Lancel, S.; Eeckhoute, J.; Hesselink, M.K.C.; Paquet, C.; Delhaye, S.; Shin, Y.; et al. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 2013, 19, 1039–1046.
126. Vieira, E.; Marroquí, L.; Batista, T.M.; Caballero-Garrido, E.; Carneiro, E.M.; Boschero, A.C.; Nadal, A.; Quesada, I. The clock gene Rev-erbα regulates pancreatic β-cell function: Modulation by leptin and high-fat diet. Endocrinology 2012, 153, 592–601.
127. Scheiermann, C.; Kunisaki, Y.; Frenette, P.S. Circadian control of the immune system. Nat. Rev. Immunol. 2013, 13, 190–198.